Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
3.
Allergy ; 77(1): 173-185, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-34080210

RESUMO

BACKGROUND: It is unclear whether asthma and its allergic phenotype are risk factors for hospitalization or severe disease from SARS-CoV-2. METHODS: All patients over 28 days old testing positive for SARS-CoV-2 between March 1 and September 30, 2020, were retrospectively identified and characterized through electronic analysis at Stanford. A sub-cohort was followed prospectively to evaluate long-term COVID-19 symptoms. RESULTS: 168,190 patients underwent SARS-CoV-2 testing, and 6,976 (4.15%) tested positive. In a multivariate analysis, asthma was not an independent risk factor for hospitalization (OR 1.12 [95% CI 0.86, 1.45], p = .40). Among SARS-CoV-2-positive asthmatics, allergic asthma lowered the risk of hospitalization and had a protective effect compared with non-allergic asthma (OR 0.52 [0.28, 0.91], p = .026); there was no association between baseline medication use as characterized by GINA and hospitalization risk. Patients with severe COVID-19 disease had lower eosinophil levels during hospitalization compared with patients with mild or asymptomatic disease, independent of asthma status (p = .0014). In a patient sub-cohort followed longitudinally, asthmatics and non-asthmatics had similar time to resolution of COVID-19 symptoms, particularly lower respiratory symptoms. CONCLUSIONS: Asthma is not a risk factor for more severe COVID-19 disease. Allergic asthmatics were half as likely to be hospitalized with COVID-19 compared with non-allergic asthmatics. Lower levels of eosinophil counts (allergic biomarkers) were associated with a more severe COVID-19 disease trajectory. Recovery was similar among asthmatics and non-asthmatics with over 50% of patients reporting ongoing lower respiratory symptoms 3 months post-infection.


Assuntos
Asma , COVID-19 , Asma/diagnóstico , Asma/epidemiologia , Teste para COVID-19 , Humanos , Fenótipo , Estudos Retrospectivos , SARS-CoV-2
5.
Front Immunol ; 12: 684657, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34489935

RESUMO

Pulmonary arterial hypertension (PAH) is a chronic, incurable condition characterized by pulmonary vascular remodeling, perivascular inflammation, and right heart failure. Regulatory T cells (Tregs) stave off autoimmunity, and there is increasing evidence for their compromised activity in the inflammatory milieu of PAH. Abnormal Treg function is strongly correlated with a predisposition to PAH in animals and patients. Athymic Treg-depleted rats treated with SU5416, an agent causing pulmonary vascular injury, develop PAH, which is prevented by infusing missing CD4+CD25highFOXP3+ Tregs. Abnormal Treg activity may also explain why PAH disproportionately affects women more than men. This mini review focuses on the role of Tregs in PAH with a special view to sexual dimorphism and the future promise of Treg therapy.


Assuntos
Hipertensão Arterial Pulmonar/imunologia , Hipertensão Arterial Pulmonar/prevenção & controle , Linfócitos T Reguladores/imunologia , Lesões do Sistema Vascular/imunologia , Lesões do Sistema Vascular/prevenção & controle , Animais , Autoimunidade , Endotélio Vascular/imunologia , Endotélio Vascular/patologia , Humanos , Indóis/efeitos adversos , Hipertensão Arterial Pulmonar/patologia , Pirróis/efeitos adversos , Ratos , Caracteres Sexuais , Lesões do Sistema Vascular/patologia
6.
Front Immunol ; 11: 601584, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33224153

RESUMO

Introduction: Macrophage expressed gene 1 (MPEG1) is highly expressed in macrophages and other phagocytes. The gene encodes a bactericidal pore-forming protein, dubbed Perforin-2. Structural-, animal-, and cell-based studies have established that perforin-2 facilitates the destruction of phagocytosed microbes upon its activation within acidic phagosomes. Relative to wild-type controls, Mpeg1 knockout mice suffer significantly higher mortality rates when challenged with gram-negative or -positive pathogens. Only four variants of MPEG1 have been functionally characterized, each in association with pulmonary infections. Here we report a new MPEG1 non-sense variant in a patient with the a newly described association with persistent polymicrobial infections of the skin and soft tissue. Case Description: A young adult female patient was evaluated for recurrent abscesses and cellulitis of the breast and demonstrated a heterozygous, rare variant in MPEG1 p.Tyr430*. Multiple courses of broad-spectrum antimicrobials and surgical incision and drainage failed to resolve the infection. Functional studies revealed that the truncation variant resulted in significantly reduced capacity of the patient's phagocytes to kill intracellular bacteria. Patient-derived macrophages responded to interferon gamma (IFN-γ) by significantly increasing the expression of MPEG1. IFN-γ treatment supported perforin-2 dependent bactericidal activity and wound healing. Conclusions: This case expands the phenotype of MPEG1 deficiency to include severe skin and soft tissue infection. We showed that haploinsufficiency of perforin-2 reduced the bactericidal capacity of human phagocytes. Interferon-gamma therapy increases expression of perforin-2, which may compensate for such variants. Thus, treatment with IFN-γ could help prevent infections.


Assuntos
Candidíase Cutânea/genética , Coinfecção/genética , Haploinsuficiência , Imunidade Inata/genética , Proteínas de Membrana/genética , Fagócitos/imunologia , Proteínas Citotóxicas Formadoras de Poros/genética , Dermatopatias Bacterianas/genética , Candidíase Cutânea/tratamento farmacológico , Candidíase Cutânea/imunologia , Candidíase Cutânea/microbiologia , Coinfecção/tratamento farmacológico , Coinfecção/imunologia , Coinfecção/microbiologia , Feminino , Predisposição Genética para Doença , Humanos , Imunidade Inata/efeitos dos fármacos , Interferon gama/uso terapêutico , Fagócitos/efeitos dos fármacos , Fagócitos/microbiologia , Fenótipo , Dermatopatias Bacterianas/tratamento farmacológico , Dermatopatias Bacterianas/imunologia , Dermatopatias Bacterianas/microbiologia , Resultado do Tratamento , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...